Skip to main content

Glycocalyx Damage Estimated Using Colloidal Iron Staining

The full text article is not available for purchase.

The publisher only permits individual articles to be downloaded by subscribers.

Anionic constituents in the peritubular capillary basement membranes and the glomerular endothelial cells have been demonstrated to function as a size- and charge-selective barrier. Cationic colloidal iron staining of human biopsy specimens revealed a glycocalyx on the surface of the glomerular basement membrane (GBM), peritubular capillary (PTC) endothelial cells, and brush border of the tubular epithelial cells of normal kidney. However, the glycocalyx was abolished in the PTC wall of C4d-positive acute humoral rejected kidney, and in the GBM as well as the PTC wall of a chronic, allograft, nephropathy kidney. In addition, cyclosporine eliminated the glycocalyx in the PTC wall, while treatment with heparin inhibited the elimination of the PTC glycocalyx. In conclusion, the glycocalyx on the surface of the GBM and PTC is an important component in the endothelial cell barrier.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Chronic allograft nephropathy; Cyclosporine; Glycocalyx; Humoral rejection; Transplantation

Document Type: Research Article

Affiliations: 1: Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka, Japan, Beijing Friendship Hospital, The Capital Medical University, Beijing, China 2: Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka, Japan, Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan 3: Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan 4: Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan 5: Beijing Friendship Hospital, The Capital Medical University, Beijing, China 6: Department of Human Morphology, Okayama University School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 7: Department of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka, Japan

Publication date: 01 January 2008

More about this publication?
  • Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.

    Cell Transplantation is now being published by SAGE. Please visit their website for the most recent issues.

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more